Document is current
Any future updates will be listed below
-
Authors
Senapati, Jayastu
Konopleva, Marina
Issa, Ghayas C.
Jabbour, Elias
Kadia, Tapan
DiNardo, Courtney
Borthakur, Gautam
Pemmaraju, Naveen
Short, Nicholas J.
Yilmaz, Musa
Deshmukh, Indraneel
Alvarez, Joie
Loghavi, Sanam
Tang, Guilin
Abbas, Hussein A.
Andreeff, Michael
Bhalla, Kapil
Midde, Narasimha M.
Said, Nabil
Noyalis, Amy
Mires, Derek E.
Ning, Jing
Xiao, Lianchun
Ravandi, Farhad
Garcia-Manero, Guillermo
Kantarjian, Hagop M.
Daver, Naval G.
-
Funding
Funding for this research was provided by:
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson Cancer Center Grant (CA016672)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
University of Texas MD Anderson SPORE (C1100632)
Daiichi Sankyo
- License Information
-
More Information
Article History
Received: 26 August 2025
Accepted: 23 October 2025
First Online: 27 November 2025
Declarations
:
: GCI reports personal/consulting fees from Novartis, Sanofi, and Syndax and data and safety monitoring for Novartis outside the submitted work. TMK reports grants/contracts from Ascentage Pharma, Bristol Myers Squibb Company, Genentech, Incyte Corporation, and Jazz Pharmaceuticals; and personal/consulting fees from AbbVie, Agios Pharmaceuticals Inc., Daiichi Sankyo Company, Genentech, Novartis, Servier Pharmaceuticals, and Syndax outside the submitted work. CDD reports grants/contracts and research funding from AbbVie, Astex, BeiGene, Bristol Myers Squibb Company, Foghorn, ImmuneOnc, Remix Rigel, Servier, and Schrodinger; personal/consulting fees from AbbVie, Astellas Pharma Inc., AstraZeneca BeiGene, Bristol Myers Squibb Company, Genmab, GlaxoSmithKline, Molecular Partners, Ryvu, Schrodinger, Servier, and Stemline; honoraria from AbbVie, Astellas Pharma Inc., Bristol Myers Squibb Company, Jazz Pharmaceuticals, and Servier; support for attending meetings/travel from Servier; and service on a Data Safety Board at Genmab outside the submitted work. NP reports grants/contracts from the US Department of Defense; personal/consulting fees from AbbVie, Bristol Myers Squibb Company, GSK Consulting, Immunogen, Incyte Corporation, Johnson & Johnson, Karyopharm Therapeutics, Morphosys, OPNA, Protagonist Therapeutics, Sobi, Takeda Oncology, and Total CME; and support for other professional activities from CTI BioPharma, Dan’s House of Hope, Menarini Group, and Payclex outside the submitted work. NJS reports grants/contracts and research funding from Ascentage, Astellas Pharma Inc., GlaxoSmithKline, Hemogenyx, NextCure, Novartis, Stemline Therapeutics Inc., Takeda Oncology, Vironexis and Xencor; personal/consulting fees from Adaptive Biotechnologies, Amgen, Autolus, GlaxoSmithKline, Novartis, PFIZER CANADA INC., and Pfizer Inc.; and honoraria from Adaptive Biotechnologies, Amgen, Astellas Pharma Inc., Pfizer Inc., Sanofi, and Takeda Oncology outside the submitted work. SL reports grants/contracts from Amgen and Astellas Pharma; personal/consulting fees from AbbVie, AlphaSight, Aptitude Health, Arima, Blueprint Medicine, Bristol Myers Squibb Company, Caris Diagnostics, Daiichi Sankyo Company, Gerson Lehrman Group, Guidepoint, Kura Oncology, Opinion Health, Qiagen Inc., QualWorld, Recordati Rare Diseases Inc., Servier Affaires Medicales, Stemline Therapeutics Inc., Syndax, and Tempus; and owns stock in AbbVie and PureTech outside the submitted work. HAA reports research support from Ascentage, Blueprint Medicines, Genentech, Enzyme-By-Design, Genentech, GlaxoSmithKline, and Illumina; personal/consulting or advisory fees from Cogent Biosciences and Molecular Partners; honoraria from Alamar Biotechnology and Illumina; and in-kind support from Illumina outside the submitted work. NM, NS, AN and DM are employed with Daiichi Sankyo. FR reports grants/contracts from Bristol Myers Squibb Company and Taiho Pharmaceutical; personal/consulting fees from Amgen, Astellas Pharma, Bristol Myers Squibb Company, Celgene Corporation, Novartis Foundation, and Taiho Pharmaceutical; and support for other professional activities from Celgene Corporation outside the submitted work. HMK reports institutional grants from AbbVie, Amgen, Ascentage, Bristol Myers Squibb Company, Daiichi Sankyo Company, Immunogen, and Novartis; personal/consulting fees from AbbVie, Amgen, Ascentage, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Target Rx, Stemline, and Takeda Oncology outside the submitted work. NGD reports grants/contracts from AbbVie Inc., Amgen, Astellas Pharma, Bristol Myers Squibb Company, Daiichi Sankyo Company, FATE Therapeutics, Genentech, Gilead Sciences Inc., Glycomimetics, Hanmi, ImmunoGen Inc., Kite Pharma Inc., Novimmune, Pfizer Inc., Servier Pharmaceuticals LLC, Trillium, and Trovagene; and personal/consulting fees from AbbVie, Agios Pharmaceuticals Inc., Amgen, Arog Pharmaceuticals, Astellas Pharma, Bristol Myers Squibb Company, Celgene, Daiichi Sankyo Company, Genentech, Gilead Sciences Inc., ImmunoGen Inc., Jazz Pharmaceuticals, Kite Pharma Inc., Novartis, Pfizer Inc., Servier Pharmaceuticals LLC, Shattuck Labs, Stemline/Menarini, Syndax, and Trillium outside the submitted work. The remaining authors disclosed no conflicts of interest.
